urvey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strateg

Autor(es):Mostrar menos -

Dorlass, Erick Gustavo ^[1] ; Lourenco, Karine Lima ^[2] ; Miserani Magalhaes, Rubens Daniel ^[2] ; Sato, Hugo ^[2] ; Fiorini, Alex ^[2] ; Peixoto, Renata ^[2] ; Coelho, Helena Perez ^[2] ; Telezynski, Bruna Larotonda ^[1] ; Scagion, Guilherme Pereira ^[1] ; Ometto, Tatiana ^[1] ; Thomazelli, Luciano Matsumiya ^[1] ; Leal Oliveira, Danielle Bruna ^[3] ; Fernandes, Ana Paula ^[2] ; Durigon, Edison Luiz ^[1] ; Fonseca, Flavio Guimaraes ^[2] ; Ribeiro Teixeira, Santuza Maria ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sao Paulo - Brazil

^[2] Univ Fed Minas Gerais, Ctr Tecnol Vacinas, Rua Prof Jose Vieira de Mendonca 770, BR-31310260 Belo Horizonte, MG - Brazil

^[3] Hosp Israelita Albert Einstein, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Genomics; v. 113, n. 6, p. 4109-4115, NOV 2021.
• Citações Web of Science: 0

Resumo

Genetic variants of SARS-CoV-2 have been emerging and circulating in many places across the world. Rapid detection of these variants is essential since their dissemination can impact transmission rates, diagnostic procedures, disease severity, response to vaccines or patient management. Sanger sequencing has been used as the preferred approach for variant detection among circulating human immunodeficiency and measles virus genotypes. Using primers to amplify a fragment of the SARS-CoV-2 genome encoding part of the Spike protein, we showed that Sanger sequencing allowed us to rapidly detect the introduction and spread of three distinct SARSCoV-2 variants in two major Brazilian cities. In both cities, after the predominance of variants closely related to the virus first identified in China, the emergence of the P.2 variant was quickly followed by the detection of the P1 variant, which became dominant in less than one month after it was first detected. (AU)

• Processo FAPESP: 20/06409-1 - Avaliação da resposta imune humoral e da resposta inflamatória em pacientes com diagnóstico confirmado de COVID-19 no Hospital Sírio Libanês e correlação com a severidade da doença
• Beneficiário: Edison Luiz Durigon
• Modalidade de apoio: Auxílio à Pesquisa - Regular